AKR1C1-3 expression has been reported to be induced by anti-cancer agents, thus producing a consequent enhancement of the resistance mechanisms engaged by cancer cells against standard chemotherapics and the activation of survival pathways, thus facilitating cancer progression. The gene discussed is AKR1C1; the disease is cancer.